US 11,860,161 B2
Detection and treatment of autoimmune disorders
Neelufar Mozaffarian, Mercer Island, WA (US); and Anne M. Stevens, Seattle, WA (US)
Assigned to Seattle Children's Hospital, Seattle, WA (US)
Filed by Seattle Children's Hospital, Seattle, WA (US)
Filed on Aug. 5, 2019, as Appl. No. 16/532,435.
Application 13/282,334 is a division of application No. 12/243,913, filed on Oct. 1, 2008, granted, now 8,062,852.
Application 16/532,435 is a continuation of application No. 14/874,851, filed on Oct. 5, 2015, granted, now 10,371,702.
Application 14/874,851 is a continuation of application No. 13/630,364, filed on Sep. 28, 2012, granted, now 9,168,296.
Application 13/630,364 is a continuation of application No. 13/282,334, filed on Oct. 26, 2011, abandoned.
Claims priority of provisional application 60/997,334, filed on Oct. 1, 2007.
Prior Publication US 2020/0209237 A1, Jul. 2, 2020
Int. Cl. G01N 33/53 (2006.01); G01N 33/564 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); C12N 5/0784 (2010.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61B 5/00 (2006.01); A61K 31/713 (2006.01); A61K 39/395 (2006.01)
CPC G01N 33/564 (2013.01) [A61B 5/0082 (2013.01); A61B 5/4842 (2013.01); A61K 31/713 (2013.01); A61K 38/06 (2013.01); A61K 38/07 (2013.01); A61K 39/3955 (2013.01); C07K 16/2803 (2013.01); C07K 2317/76 (2013.01); G01N 2333/70503 (2013.01); G01N 2800/102 (2013.01); G01N 2800/104 (2013.01); G01N 2800/56 (2013.01); Y10S 436/811 (2013.01)] 10 Claims
 
1. A method of distinguishing between the presence of systemic lupus erythematosus (SLE) and a bacterial or viral infection comprising:
(a) obtaining a blood sample from a human subject;
(b) contacting the blood sample with a detectably labeled antibody specific for PD-L1 and at least one antibody specific for a cell surface marker on a monocyte or dendritic cell;
(c) detecting the presence or absence of monocytes or dendritic cells; and
(d) determining the amount of PD-L1 in a blood sample containing monocytes or dendritic cells, wherein a PD-L1 amount from monocytes or dendritic cells that is lower than a control value is indicative of SLE and a PD-L1 amount from monocytes or dendritic cells that is higher than the control value is indicative of a bacterial or viral infection, wherein the control value is established based on a PD-L1 amount of one or more healthy subjects.